About ATLAB Pharma
ATLAB Pharma is a company based in Nantes (France) founded in 2008 was acquired by Telix Pharma in September 2018. ATLAB Pharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Nantes, France
- SectorsHealthcare
- Email••••••••
- Website atlab-pharma.com
- Social LinkedIn
- Acquired by Telix Pharma (Sep 2018)
- Latest Funding Round$7.94M (USD), Grant
Jun 2009
- Investors
- Acquired byTelix Pharma
(Sep 2018)
Funding Insights of ATLAB Pharma
- Total Rounds 1
- Last Round Grant — $7.94M
- First Round $7.94M
(Jun 2009)
All 1 funding rounds of ATLAB Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2009 | $7.94M | Grant | – | – | – |
1 investors in total: 1 institutional.
Investors in ATLAB Pharma
ATLAB Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Telix Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Theranostic radiopharmaceuticals are developed for cancer imaging and therapy. | 2015 | telixpharma.com | Melbourne, Australia |
Investor details for ATLAB Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ATLAB Pharma
3 dated milestones of ATLAB Pharma across 10 years, from founding to its latest funding, stage changes and deals.
- Founded ATLAB Pharma is founded.
- Funding First funding round of $7.9M.
- Exit Acquired by Telix Pharma.
Competitors of ATLAB Pharma
ATLAB Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of ATLAB Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Atlab Pharma
Complete news archive for ATLAB Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ATLAB Pharma
10 companies that operate in the same segment as ATLAB Pharma (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ATLAB Pharma
ATLAB Pharma was founded in 2008 and raised its 1st funding round 1 year after it was founded.
ATLAB Pharma is headquartered in Nantes, France. It is registered at Nantes, Pays De La Loire, France.
ATLAB Pharma was founded in 2008 and is based in Nantes, France. Operations focus on the biotechnology sector, specifically radio immunotherapy for cancer. Monoclonal antibodies conjugated to radioisotopes are developed to deliver targeted radiation to tumor cells. The lead candidate, ATL101, targets prostate-specific membrane antigen using Lutetium-177 and has demonstrated safety and anti-tumor activity in Phase I and II trials for castrate-resistant prostate cancer.
ATLAB Pharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
ATLAB Pharma has 1 investor. Key investors include Telix Pharmaceuticals.
Yes. ATLAB Pharma was acquired by Telix Pharma in September 2018.